PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare bone marrow cancer
Disease control CompletedThis study looked at whether giving a JAK inhibitor drug before a donor stem cell transplant helps people with myelofibrosis, a serious bone marrow disorder. 61 patients received the drug ruxolitinib before their transplant. The goal was to improve survival and reduce complicatio…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:45 UTC
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) could help prevent graft-versus-host disease (GVHD) in 59 people with blood cancers like leukemia or myelodysplastic syndrome who received a donor stem cell transplant. GVHD oc…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 03:43 UTC
-
Drug cocktail shows promise against rare bone marrow cancers
Disease control CompletedThis study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. Participants had already tried other treatments or were at higher ri…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:40 UTC
-
Bomedemstat shows promise for Long-Term control of rare blood cancers
Disease control CompletedThis study looked at the long-term safety and effectiveness of the drug bomedemstat in 81 people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Participants had already taken bomedemstat in an earlier study and continued treatment to see how well it cont…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 17, 2026 03:38 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses chemotherapy and radiation before donor stem cells are given, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer a…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise for rare blood cancers
Disease control CompletedThis study tested a new pill called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. The goal was to see if it could shrink enlarged spleens and reduce the need for blood transfusions. The drug was given alone or with another medicine (ruxoli…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New combo therapy offers hope for hard-to-treat bone marrow cancer
Disease control CompletedThis study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis (a type of bone marrow cancer) whose disease did not respond well to standard JAK-inhibitor therapy. The goal was to see if the combination could shrink the spleen, improve sym…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 04, 2026 16:19 UTC